Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 193

Similar articles for PubMed (Select 22383668)

1.

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE; VX 08-770-104 Study Group.

Chest. 2012 Sep;142(3):718-24.

2.

Targeting ion channels in cystic fibrosis.

Mall MA, Galietta LJ.

J Cyst Fibros. 2015 Jun 23. pii: S1569-1993(15)00150-2. doi: 10.1016/j.jcf.2015.06.002. [Epub ahead of print] Review.

PMID:
26115565
3.

New and Emerging Treatments for Cystic Fibrosis.

Barry PJ, Jones AM.

Drugs. 2015 Jun 20. [Epub ahead of print]

PMID:
26091951
4.

Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.

Dupuis A, Keenan K, Ooi CY, Dorfman R, Sontag MK, Naehrlich L, Castellani C, Strug LJ, Rommens JM, Gonska T.

Genet Med. 2015 Jun 18. doi: 10.1038/gim.2015.79. [Epub ahead of print]

PMID:
26087176
5.

Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor.

Siracusa CM, Ryan J, Burns L, Wang Y, Zhang N, Clancy JP, Drotar D.

J Cyst Fibros. 2015 Jun 11. pii: S1569-1993(15)00124-1. doi: 10.1016/j.jcf.2015.05.009. [Epub ahead of print]

PMID:
26074007
6.

Rate of Uptake of Ivacaftor Use after FDA Approval among Patients Enrolled in the United States Cystic Fibrosis Foundation Patient Registry.

Sawicki GS, Dasenbrook E, Fink AK, Schechter MS.

Ann Am Thorac Soc. 2015 Jun 13. [Epub ahead of print]

PMID:
26073026
7.

Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?

Jones AM, Barry PJ.

Thorax. 2015 Jul;70(7):615-6. doi: 10.1136/thoraxjnl-2015-207369. No abstract available.

PMID:
26071414
8.

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group.

Lancet Respir Med. 2015 Jun 9. pii: S2213-2600(15)00201-5. doi: 10.1016/S2213-2600(15)00201-5. [Epub ahead of print]

PMID:
26070913
9.

The holy grail of cystic fibrosis research: pharmacological repair of the F508del-CFTR mutation.

Maiuri L, De Stefano D, Raia V, Kroemer G.

Ann Transl Med. 2015 May;3(Suppl 1):S24. doi: 10.3978/j.issn.2305-5839.2015.02.32. No abstract available.

10.

Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells.

Stanton BA, Coutermarsh B, Barnaby R, Hogan D.

PLoS One. 2015 May 27;10(5):e0127742. doi: 10.1371/journal.pone.0127742. eCollection 2015.

11.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC and TRANSPORT Study Groups..

N Engl J Med. 2015 May 17. [Epub ahead of print]

12.

Another Beginning for Cystic Fibrosis Therapy.

Davis PB.

N Engl J Med. 2015 May 17. [Epub ahead of print]

13.

F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.

Yang H, Ma T.

Expert Opin Ther Pat. 2015 May 14:1-12. [Epub ahead of print]

PMID:
25971311
14.

Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.

Bernarde C, Keravec M, Mounier J, Gouriou S, Rault G, Férec C, Barbier G, Héry-Arnaud G.

PLoS One. 2015 Apr 8;10(4):e0124124. doi: 10.1371/journal.pone.0124124. eCollection 2015.

15.

Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.

Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW.

Cochrane Database Syst Rev. 2015 Mar 26;3:CD009841. doi: 10.1002/14651858.CD009841.pub2.

PMID:
25811419
16.

Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.

Bratcher PE, Rowe SM, Reeves G, Roberts T, Szul T, Harris WT, Tirouvanziam R, Gaggar A.

J Cyst Fibros. 2015 Mar 11. pii: S1569-1993(15)00050-8. doi: 10.1016/j.jcf.2015.02.010. [Epub ahead of print]

PMID:
25769931
17.

Efficacy response in CF patients treated with ivacaftor: post-hoc analysis.

Konstan MW, Plant BJ, Elborn JS, Rodriguez S, Munck A, Ahrens R, Johnson C.

Pediatr Pulmonol. 2015 May;50(5):447-55. doi: 10.1002/ppul.23173. Epub 2015 Mar 9.

PMID:
25755212
18.

Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.

Yousef S, Solomon GM, Brody A, Rowe SM, Colin AA.

Chest. 2015 Mar;147(3):e79-82. doi: 10.1378/chest.14-1198.

PMID:
25732475
19.

[Therapeutic advances in cystic fibrosis in 2014.]

Durupt S, Mazur S, Reix P.

Rev Pneumol Clin. 2015 Feb 26. pii: S0761-8417(15)00006-1. doi: 10.1016/j.pneumo.2014.11.008. [Epub ahead of print] Review. French.

PMID:
25727661
20.

Drug-drug plasma protein binding interactions of ivacaftor.

Schneider EK, Huang JX, Carbone V, Baker M, Azad MA, Cooper MA, Li J, Velkov T.

J Mol Recognit. 2015 Jun;28(6):339-48. doi: 10.1002/jmr.2447. Epub 2015 Feb 24.

PMID:
25707701
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk